• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒患者的肠道病毒组和细菌组的综合动态变化。

Integrated gut virome and bacteriome dynamics in COVID-19 patients.

机构信息

CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

University of Chinese Academy of Sciences, Beijing, China.

出版信息

Gut Microbes. 2021 Jan-Dec;13(1):1-21. doi: 10.1080/19490976.2021.1887722.

DOI:10.1080/19490976.2021.1887722
PMID:33678150
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7946006/
Abstract

SARS-CoV-2 is the cause of the current global pandemic of COVID-19; this virus infects multiple organs, such as the lungs and gastrointestinal tract. The microbiome in these organs, including the bacteriome and virome, responds to infection and might also influence disease progression and treatment outcome. In a cohort of 13 COVID-19 patients in Beijing, China, we observed that the gut virome and bacteriome in the COVID-19 patients were notably different from those of five healthy controls. We identified a bacterial dysbiosis signature by observing reduced diversity and viral shifts in patients, and among the patients, the bacterial/viral compositions were different between patients of different severities, although these differences are not entirely distinguishable from the effect of antibiotics. Severe cases of COVID-19 exhibited a greater abundance of opportunistic pathogens but were depleted for butyrate-producing groups of bacteria compared with mild to moderate cases. We replicated our findings in a mouse COVID-19 model, confirmed virome differences and bacteriome dysbiosis due to SARS-CoV-2 infection, and observed that immune/infection-related genes were differentially expressed in gut epithelial cells during infection, possibly explaining the virome and bacteriome dynamics. Our results suggest that the components of the microbiome, including the bacteriome and virome, are affected by SARS-CoV-2 infections, while their compositional signatures could reflect or even contribute to disease severity and recovery processes.

摘要

SARS-CoV-2 是当前 COVID-19 全球大流行的病原体;该病毒感染多个器官,如肺部和胃肠道。这些器官中的微生物组,包括细菌组和病毒组,会对感染作出反应,也可能影响疾病进展和治疗效果。在中国北京的 13 例 COVID-19 患者队列中,我们观察到 COVID-19 患者的肠道病毒组和细菌组与 5 名健康对照者有显著差异。我们通过观察患者中多样性降低和病毒转移,确定了细菌失调的特征,并且在患者中,严重程度不同的患者的细菌/病毒组成不同,尽管这些差异并不能完全归因于抗生素的影响。与轻度至中度病例相比,严重 COVID-19 病例表现出更多机会性病原体的丰度增加,但产丁酸的细菌群减少。我们在 COVID-19 小鼠模型中复制了我们的发现,证实了由于 SARS-CoV-2 感染导致的病毒组差异和细菌组失调,并且观察到在感染过程中肠道上皮细胞中免疫/感染相关基因的表达存在差异,这可能解释了病毒组和细菌组的动态变化。我们的研究结果表明,包括细菌组和病毒组在内的微生物组成分受到 SARS-CoV-2 感染的影响,而其组成特征可能反映甚至有助于疾病的严重程度和恢复过程。

相似文献

1
Integrated gut virome and bacteriome dynamics in COVID-19 patients.新冠病毒患者的肠道病毒组和细菌组的综合动态变化。
Gut Microbes. 2021 Jan-Dec;13(1):1-21. doi: 10.1080/19490976.2021.1887722.
2
The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection.儿童肠道细菌群落和病毒群落对SARS-CoV-2感染的反应
Front Cell Infect Microbiol. 2024 Jan 22;14:1335450. doi: 10.3389/fcimb.2024.1335450. eCollection 2024.
3
Characterizations of the Gut Bacteriome, Mycobiome, and Virome in Patients with Osteoarthritis.肠道细菌组、真菌组和病毒组在骨关节炎患者中的特征。
Microbiol Spectr. 2023 Feb 14;11(1):e0171122. doi: 10.1128/spectrum.01711-22. Epub 2022 Dec 14.
4
Alterations in the Composition of Intestinal DNA Virome in Patients With COVID-19.肠道 DNA 病毒组在 COVID-19 患者中的组成变化。
Front Cell Infect Microbiol. 2021 Nov 24;11:790422. doi: 10.3389/fcimb.2021.790422. eCollection 2021.
5
Alterations in the Gut Virome in Obesity and Type 2 Diabetes Mellitus.肥胖症和 2 型糖尿病中肠道病毒组的改变。
Gastroenterology. 2021 Oct;161(4):1257-1269.e13. doi: 10.1053/j.gastro.2021.06.056. Epub 2021 Jun 25.
6
Gut virome and microbiome dynamics before and after SARS-CoV-2 infection in women living with HIV and their infants.女性 HIV 感染者及其婴儿在感染 SARS-CoV-2 前后的肠道病毒组和微生物组动态。
Gut Microbes. 2024 Jan-Dec;16(1):2394248. doi: 10.1080/19490976.2024.2394248. Epub 2024 Aug 26.
7
Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity.人类肠道 RNA 和 DNA 病毒组在 SARS-CoV-2 感染及严重程度中的时变景观。
Microbiome. 2021 Apr 14;9(1):91. doi: 10.1186/s40168-021-01008-x.
8
Gut virome alterations in patients with chronic obstructive pulmonary disease.慢性阻塞性肺疾病患者的肠道病毒组改变。
Microbiol Spectr. 2024 Jul 2;12(7):e0428723. doi: 10.1128/spectrum.04287-23. Epub 2024 May 24.
9
Virome and bacteriome: two sides of the same coin.病毒组和细菌组:同一枚硬币的两面。
Curr Opin Virol. 2019 Aug;37:37-43. doi: 10.1016/j.coviro.2019.05.007. Epub 2019 Jun 6.
10
The gut virome in Irritable Bowel Syndrome differs from that of controls.肠病毒组在肠易激综合征患者中与对照者不同。
Gut Microbes. 2021 Jan-Dec;13(1):1-15. doi: 10.1080/19490976.2021.1887719.

引用本文的文献

1
Gut microbiota and viral respiratory infections: microbial alterations, immune modulation, and impact on disease severity: a narrative review.肠道微生物群与病毒性呼吸道感染:微生物变化、免疫调节及对疾病严重程度的影响:一项叙述性综述
Front Microbiol. 2025 Jul 18;16:1605143. doi: 10.3389/fmicb.2025.1605143. eCollection 2025.
2
The gut virome and human health: From diversity to personalized medicine.肠道病毒组与人类健康:从多样性到个性化医学。
Eng Microbiol. 2025 Feb 7;5(1):100191. doi: 10.1016/j.engmic.2025.100191. eCollection 2025 Mar.
3
Immunomodulatory effects of gut microbiota on vaccine efficacy against respiratory pathogens.

本文引用的文献

1
Multivariable association discovery in population-scale meta-omics studies.基于人群的宏基因组学研究中的多变量关联发现。
PLoS Comput Biol. 2021 Nov 16;17(11):e1009442. doi: 10.1371/journal.pcbi.1009442. eCollection 2021 Nov.
2
Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19.描绘 COVID-19 患者中 SARS-CoV-2 粪便病毒活性与肠道微生物群落组成的关系。
Gut. 2021 Feb;70(2):276-284. doi: 10.1136/gutjnl-2020-322294. Epub 2020 Jul 20.
3
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
肠道微生物群对针对呼吸道病原体疫苗效力的免疫调节作用。
Front Immunol. 2025 Jun 3;16:1618921. doi: 10.3389/fimmu.2025.1618921. eCollection 2025.
4
Gut microbiota alterations are linked to COVID-19 severity in North African and European populations.肠道微生物群的改变与北非和欧洲人群中新冠肺炎的严重程度有关。
NPJ Biofilms Microbiomes. 2025 Jun 13;11(1):106. doi: 10.1038/s41522-025-00733-7.
5
Fecal Microbiota Transplantation Using Donor Stool Obtained from Exercised Mice Suppresses Colonic Tumor Development Induced by Azoxymethane in High-Fat Diet-Induced Obese Mice.使用从运动小鼠获得的供体粪便进行粪便微生物群移植可抑制高脂饮食诱导的肥胖小鼠中由氧化偶氮甲烷诱导的结肠肿瘤发展。
Microorganisms. 2025 Apr 27;13(5):1009. doi: 10.3390/microorganisms13051009.
6
Alterations of the gut commensal in patients with COVID-19.新冠病毒疾病(COVID-19)患者肠道共生菌的改变
Virulence. 2025 Dec;16(1):2505999. doi: 10.1080/21505594.2025.2505999. Epub 2025 May 18.
7
Relationship Between Gut Microbiota and the Clinical Course of COVID-19 Disease.肠道微生物群与COVID-19疾病临床进程之间的关系
Viruses. 2025 Apr 2;17(4):520. doi: 10.3390/v17040520.
8
The Chinese gut virus catalogue reveals gut virome diversity and disease-related viral signatures.中国肠道病毒目录揭示了肠道病毒组的多样性和与疾病相关的病毒特征。
Genome Med. 2025 Mar 26;17(1):30. doi: 10.1186/s13073-025-01460-6.
9
Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的免疫和炎症后果及其在肾脏疾病中的意义。
Front Immunol. 2025 Feb 12;15:1376654. doi: 10.3389/fimmu.2024.1376654. eCollection 2024.
10
The relationship between gut and nasopharyngeal microbiome composition can predict the severity of COVID-19.肠道微生物群与鼻咽微生物群组成之间的关系可以预测新冠肺炎的严重程度。
Elife. 2025 Feb 18;13:RP95292. doi: 10.7554/eLife.95292.
通用设计的贝塔冠状病毒疫苗,用于预防 COVID-19、MERS 和 SARS。
Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28.
4
Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza.2019 年冠状病毒病或 H1N1 流感患者肠道微生物组的改变。
Clin Infect Dis. 2020 Dec 17;71(10):2669-2678. doi: 10.1093/cid/ciaa709.
5
APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort.APOE e4基因型在英国生物银行社区队列中可预测严重的2019冠状病毒病。
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2231-2232. doi: 10.1093/gerona/glaa131.
6
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.一种基于重组腺病毒 5 型的 COVID-19 疫苗的安全性、耐受性和免疫原性:一项剂量递增、开放标签、非随机、首次人体试验。
Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020 May 22.
7
Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization.COVID-19 患者住院期间肠道微生物组的变化。
Gastroenterology. 2020 Sep;159(3):944-955.e8. doi: 10.1053/j.gastro.2020.05.048. Epub 2020 May 20.
8
Gut microbiota and Covid-19- possible link and implications.肠道微生物群与新冠病毒(COVID-19):可能的联系及影响。
Virus Res. 2020 Aug;285:198018. doi: 10.1016/j.virusres.2020.198018. Epub 2020 May 13.
9
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
10
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.